Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

News

News
FDA Advisory Committee Recommends Approval of Adrenoleukodystrophy Treatment
07/01/2022
An FDA advisory panel unanimously recommended the approval of the investigational gene therapy elivaldogene autotemcel (eli-cel) for the treatment of early active cerebral adrenoleukodystrophy in pediatric patients.
An FDA advisory panel unanimously recommended the approval of the investigational gene therapy elivaldogene autotemcel (eli-cel) for the treatment of early active cerebral adrenoleukodystrophy in pediatric patients.
An FDA advisory panel...
07/01/2022
Neurology
News
ALS Treatment Trials May Require More Complex Statistical Models
06/28/2022
The inability of placebo-to-active treatment crossover trials, involving patients with fatal conditions such as amyotrophic lateral sclerosis (ALS), to sustain a placebo group long enough to accurately assess survival may lead to an...
The inability of placebo-to-active treatment crossover trials, involving patients with fatal conditions such as amyotrophic lateral sclerosis (ALS), to sustain a placebo group long enough to accurately assess survival may lead to an...
The inability of...
06/28/2022
Neurology
News
Pandemic Babies Scored Lower on Neurodevelopmental Screeners Than Their Predecessors
06/28/2022
Birth during the COVID-19 pandemic, but not in utero exposure to maternal SARS-CoV-2 infection, is associated with lower scores on several neurodevelopment screener subdomains at age 6 months.
Birth during the COVID-19 pandemic, but not in utero exposure to maternal SARS-CoV-2 infection, is associated with lower scores on several neurodevelopment screener subdomains at age 6 months.
Birth during the COVID-19...
06/28/2022
Neurology

Advertisement

News
FDA Subcommittee Votes Against Pimavanserin for Alzheimer Disease Psychosis Therapy
06/28/2022
FDA Psychopharmacologic Drugs Advisory Committee (PDAC) voted 9 to 3 that there is not sufficient evidence pimavanserin is effective in the treatment of hallucinations and delusions associated with Alzheimer disease psychosis.
FDA Psychopharmacologic Drugs Advisory Committee (PDAC) voted 9 to 3 that there is not sufficient evidence pimavanserin is effective in the treatment of hallucinations and delusions associated with Alzheimer disease psychosis.
FDA Psychopharmacologic Drugs...
06/28/2022
Psych Congress Network
News
ALS Assessments Should Include Comprehensive Sensory Testing, Researchers Advise
06/23/2022
Neuroimaging of patients with amyotrophic lateral sclerosis (ALS) showed degeneration of anatomical structures involved in somatosensory, visual, and auditory processing.
Neuroimaging of patients with amyotrophic lateral sclerosis (ALS) showed degeneration of anatomical structures involved in somatosensory, visual, and auditory processing.
Neuroimaging of patients with...
06/23/2022
Neurology
News
Comorbid Sleep Disorders Common in Chronic Migraine Patients
06/22/2022
Patients with chronic migraine, as compared to episodic migraine, displayed higher rates of comorbid sleep disorders, including obstructive sleep apnea (OSA) and insomnia.
Patients with chronic migraine, as compared to episodic migraine, displayed higher rates of comorbid sleep disorders, including obstructive sleep apnea (OSA) and insomnia.
Patients with chronic migraine,...
06/22/2022
Neurology

Advertisement

News
As Understanding of ALS Grows, Novel Therapies Anticipated
06/15/2022
Since the discovery of SOD1 nearly 30 years ago, the identification of genes linked with amyotrophic lateral sclerosis (ALS) has progressed from a fairly slow start to the current period of quickly emerging insight.
Since the discovery of SOD1 nearly 30 years ago, the identification of genes linked with amyotrophic lateral sclerosis (ALS) has progressed from a fairly slow start to the current period of quickly emerging insight.
Since the discovery of SOD1...
06/15/2022
Neurology
News
RAAS Inhibitors May Lower Risk of Intracranial Aneurysm Rupture
06/15/2022
Renin-angiotensin-aldosterone system (RAAS) inhibitors were linked with a significant decreased rupture risk in patients with hypertension and intracranial aneurysms, according to findings from a retrospective study published in Hypertension.
Renin-angiotensin-aldosterone system (RAAS) inhibitors were linked with a significant decreased rupture risk in patients with hypertension and intracranial aneurysms, according to findings from a retrospective study published in Hypertension.
Renin-angiotensin-aldosterone...
06/15/2022
Neurology
News
Access to Medical Marijuana Improved Insomnia, but No Change to Pain, Anxiety
06/14/2022
Patients granted immediate access to medical marijuana exhibited improved self-reported sleep quality and mental well-being, but also displayed higher incidence and severity of cannabis use disorder (CUD), new research says.
Patients granted immediate access to medical marijuana exhibited improved self-reported sleep quality and mental well-being, but also displayed higher incidence and severity of cannabis use disorder (CUD), new research says.
Patients granted immediate...
06/14/2022
Neurology

Advertisement

News
Delirium Episodes in Elderly Patients Linked to Substantial Dementia Risk Within 5 Years
06/08/2022
Episodes of delirium are closely linked to future development of dementia, according to a new study published in the Journal of Neurology, Neurosurgery, & Psychiatry.
Episodes of delirium are closely linked to future development of dementia, according to a new study published in the Journal of Neurology, Neurosurgery, & Psychiatry.
Episodes of delirium are closely...
06/08/2022
Neurology

Advertisement

Advertisement

News

Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
News
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
11/05/2024
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes...
11/05/2024
Psych Congress Network
Alone or Together, CBT and Modafinil Improve MS-Related Fatigue
News
Alone or Together, CBT and Modafinil Improve MS-Related Fatigue
11/01/2024
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
The wake-promoting drug...
11/01/2024
Neurology
Gene therapy
News
Concerns Linger After Gene Therapy Shows Long-Term Benefit for Cerebral Adrenoleukodystrophy
10/28/2024
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Elivaldogene autotemcel...
10/28/2024
Neurology
Patient with family
News
During Recovery, Stroke Patients Benefit from Supportive Social Networks
10/24/2024
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke. “In aging...
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke. “In aging...
Large networks of family and...
10/24/2024
Neurology
International Stroke Burden Saw Hike Over Last 30 Years
News
International Stroke Burden Saw Hike Over Last 30 Years
10/22/2024
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
International stroke burden has...
10/22/2024
Neurology
Hands holding a head in profile with an illustrated heart over brain
News
Antiseizure Meds May Increase Cardiovascular Risk in Older Adults With Epilepsy
10/21/2024
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
A lifetime history of epilepsy...
10/21/2024
Neurology
FDA approval stamp
News
FDA Approves Infusion Treatment for Advanced Parkinson Disease in Adults
10/18/2024
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa...
10/18/2024
Neurology
Investigational Drug Improves Motor Function in Patients With SMA
News
Investigational Drug Improves Motor Function in Patients With SMA
10/16/2024
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Apitegromab, an investigational...
10/16/2024
Neurology
Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS
News
Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS
10/15/2024
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to...
10/15/2024
Neurology
An orange prescription container with generic pills spilling out in front of it
News
Masked Taper Plus CBT for Insomnia Effective in Benzodiazepine Discontinuation
10/10/2024
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined...
10/10/2024
Psych Congress Network

Advertisement

Advertisement

Alzheimer's Disease CME Series

Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
11/12/2020
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/12/2020
Neurology
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology
11/12/2020
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease...
11/12/2020
Neurology
Claim-Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
11/12/2020
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early...
11/12/2020
Neurology
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
11/10/2020
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 
Current Treatment Limitations...
11/10/2020
Neurology

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use